Population-based serology reveals risk factors for RSV infection in children younger than 5 years.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 04 2021
26 04 2021
Historique:
received:
06
01
2021
accepted:
08
04
2021
entrez:
27
4
2021
pubmed:
28
4
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization in infants. Underlying risk factors for RSV infection in the general population are not well understood, as previous work has focused on severe outcomes of infection in a clinical setting. Here we use RSV-specific IgG and IgA antibody measurements from two population-based cross-sectional serosurveys carried out in the Netherlands (n = 682) to classify children up to 5 years as seronegative or seropositive. We employ a generalized additive model to estimate the probability of prior RSV infection as function of age, date of birth within the year, and other risk factors. The analyses show that the majority of children have experienced a RSV infection before the age of 2 years. Age and birthdate are strong predictors of RSV infection in the first years of life, and children born in summer have higher estimated probability of infection than those born in winter [e.g., 0.56 (95% CI 0.45-0.66) vs. 0.32 (0.21-0.45) at age 1 year]. Our analyses reveal that the mean age at infection depends on date of birth, which has implications for the design of vaccination programmes and prioritisation schemes for the prophylactic use of monoclonal antibodies.
Identifiants
pubmed: 33903695
doi: 10.1038/s41598-021-88524-w
pii: 10.1038/s41598-021-88524-w
pmc: PMC8076290
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin A
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8953Références
J Infect Dis. 2020 Sep 23;:
pubmed: 32964923
J Infect Dis. 2018 Jan 4;217(2):238-244
pubmed: 29112722
Epidemiol Infect. 2015 Mar;143(4):804-12
pubmed: 24901443
Am J Epidemiol. 2012 Nov 1;176(9):794-802
pubmed: 23059788
PLoS One. 2017 May 22;12(5):e0177803
pubmed: 28531224
Vaccine. 2003 Jul 28;21(24):3365-9
pubmed: 12850341
J Infect Dis. 2021 Feb 12;:
pubmed: 33576788
J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583
pubmed: 30880339
J Infect Dis. 2020 Oct 7;222(Suppl 7):S688-S694
pubmed: 32821916
J Infect Dis. 2020 Oct 7;222(Suppl 7):S599-S605
pubmed: 32815542
BMC Infect Dis. 2019 May 28;19(1):470
pubmed: 31138148
Acta Paediatr. 2003 Nov;92(11):1314-21
pubmed: 14696852
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Epidemiol Infect. 2016 Jun;144(8):1622-33
pubmed: 26732801
mSphere. 2019 Apr 24;4(2):
pubmed: 31019002
Lancet Glob Health. 2017 Oct;5(10):e984-e991
pubmed: 28911764
BMJ Open. 2016 Jun 02;6(6):e009337
pubmed: 27256085
mSphere. 2019 Sep 11;4(5):
pubmed: 31511367
Pediatr Infect Dis J. 2004 Sep;23(9):806-14
pubmed: 15361717
Infect Dis Ther. 2016 Sep;5(3):271-98
pubmed: 27480325